Pharmacological treatment of pulmonary hypertension at a turning point

Folia Pharmacologica Japonica

Volumn 143, Issue 4, 2014, Pages 165-172

  Watanabe, Hiroshi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NOTE; PULMONARY HYPERTENSION;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; CARBOLINES; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; PHENYLPROPIONATES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PURINES; PYRIDAZINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; SULFONAMIDES; SULFONES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84898036400     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.143.165     Document Type: Note

References (15)

1. http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf
2. Badesch DB, et al. Chest. 2007;131:917-928.
3. Christman BW, et al. N Engl J Med. 1992;327:70-75.
4. Barst RJ, et al. N Engl J Med. 1996;334:296-302.
5. McLaughlin VV, et al. N Engl J Med. 1998;338:273-277.
6. Barst RJ, et al. J Am Coll Cardiol. 2003;41:2119-2125.
7. Watanabe H. Intern Med. 2004;43:891-893.
8. Channick RN, et al. Lancet. 2001;358:1119-1123.
9. Sitbon O, et al. Thorax. 2005; 60:1025-1030.
10. Galiè N, et al. Circulation. 2008;117:3010-3019.
11. Pulido T, et al. N Engl J Med. 2013;369:809-818.
12. Galie N, et al. N Engl J Med. 2005;353:2148-2157.
13. Galiè N, et al. Circulation. 2009;119:2894-2903.
14. Watanabe H, et al. Clin Pharmacol Ther. 2002;71:398-402.
15. Rich S, et al. N Engl J Med. 1992;327:76-81.